ZOMETA® Helps Reduce the Threat of SREs in Patients With Advanced Prostate Cancer
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
About ZOMETA: defend against SREs across a broad range of tumour types

Page  1 2


As new treatments extend survival, the threat of SREs increases

  • For patients with good performance status and metastatic disease confined to the axial skeleton, median survival is more than 4 years4
  • Without treatment, the median time to first SRE in men with bone metastases from prostate cancer is less than 11 months2


Median time to first SRE vs median survival in advanced prostate cancer2,4

*Median survival in men with good performance status and disease
confined to bone that affects the axial skeleton (treatment regimen
not specified).





Page  1 2